Abstract INTRODUCTION Proline‐rich tyrosine kinase 2 (PYK2) and focal adhesion kinase (FAK) are non‐receptor tyrosine kinases implicated in Alzheimer's disease (AD), but their functional role in microglia remains understudied. Selective pharmacological tools are required for preclinical studies leading to translational therapeutic development. METHODS We evaluated potent and selective inhibitors described in publications and patents, synthesized or procured representative compounds, and profiled them in kinase assays. In vitro physicochemical and pharmacokinetic (PK) properties were assessed, and functional effects were studied in microglial phagocytosis assays using HMC3 and BV2 microglia cellular models. RESULTS Biochemical profiling confirmed potent and selective inhibition, consistent with reported data, though assay‐dependent differences in apparent selectivity were observed. Most compounds showed favorable physicochemical and PK properties. In HMC3 assay, the PYK2‐selective tool compounds showed that strong stimulation of phagocytosis and parallel cell counts declined at non‐toxic concentrations. DISCUSSION This curated set of well‐characterized inhibitors provides a validated toolkit to probe PYK2/FAK biology in AD‐relevant models.
Weerawarna et al. (Fri,) studied this question.